AstraZeneca Signs U.S. Licensing Pact for Gout Drug
April 26 2016 - 5:28AM
Dow Jones News
By Tapan Panchal
LONDON--AstraZeneca PLC (AZN.LN) said Tuesday that it has
entered into a licensing agreement with Ironwood Pharmaceuticals
Inc. (IRWD) for the exclusive U.S. rights to Zurampic, a drug used
for the treatment of gout, a type of arthritis.
AstraZeneca said the contract includes rights to the fixed-dose
combination of lesinurad and allopurinol used for treating gout.
AstraZeneca plans to submit the fixed-dose combination program for
U.S. Food and Drug Administration review in the second half of
2016.
Under the agreement, Ironwood will pay AstraZeneca sales-related
and other milestone payments of up to $265 million and royalties on
product sales. AstraZeneca will manufacture and supply Zurampic,
provide certain support and services to Ironwood, and undertake the
regulatory approval process.
The agreement doesn't affect AstraZeneca's financial guidance
for 2016.
AstraZeneca's shares at 0839 GMT traded 1.1% lower at 4,036
pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
April 26, 2016 05:13 ET (09:13 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
